Shanghai Tongteng Biotechnology Co., Ltd. is a high-tech enterprise specializing in providing advanced equipment and consumables for biopharmaceutical R&D, pharmaceutical process development, and manufacturing.
Founded in 2018, the company currently has 800 square meters of office space in Zhangjiang, Pudong, Shanghai. Its subsidiary, Tongteng Xinchuang (Suzhou) Technology Co., Ltd., owns a 2,200-square-meter manufacturing plant in Taicang, Jiangsu.
Shanghai Tongteng Biotechnology is a major service provider in China for general laboratory equipment brands, including Singapore-based ESCO biological safety cabinets/incubators, Germany’s Cryotherm liquid nitrogen tanks, US-based Revvity microfluidic nucleic acid analyzers/small-animal in vivo imaging systems, and Cytek® flow cytometers. It provides end-to-end technical solutions covering pre-sales and after-sales services for laboratories in life sciences, biopharmaceuticals, and other industries.
Its subsidiary, Tongteng Ruijie (Shanghai) Biotechnology Co., Ltd., is a core service provider in China for many internationally renowned brands, including Germany’s Bruker Dynamic Biosensors Helix series molecular interaction analysis systems, Germany’s Cytena DISPENDIX I.DOT non-contact nanoliter liquid handling systems, and the UK’s Roylan StoragePod multi-mode compound storage pods. It provides high-end instruments and complete technical solutions from R&D to production for key industries such as life sciences, cell therapy, and biopharmaceuticals.
In early 2022, subsidiary Tongteng Xinchuang (Suzhou) Technology Co., Ltd. invested RMB 50 million to build a manufacturing plant in Taicang, Jiangsu. It has now launched and put into production self-developed products such as CEL-G® Culture Ad60/Ad600 fixed-bed bioreactors, CEL-G® TFF lab/Scientific exosome concentration systems, CEL-G® Culture MSC serum-free medium, and CelGrid™ Culture Single & Quadra micro fixed-bed bioreactors. These products provide high-quality localized R&D and production solutions for industries including cell and gene therapy, antibody and vaccine manufacturing, and extracellular vesicle (exosome) research and production.
In 2024, the Integrated Exosome Preparation Platform independently developed and put into production by Tongteng Xinchuang, through its unique 3D immobilized culture and high-efficiency purification system, brings industrial innovation to the exosome industry.
Shanghai Tongteng Biotechnology Co., Ltd. was certified as a High-Tech Enterprise in 2019 and holds 3 invention patents, 31 utility model patents, and 14 software copyrights. Tongteng Xinchuang (Suzhou) Technology Co., Ltd. holds 6 invention patents, 22 utility model patents, and 11 software copyrights. The company has obtained ISO 9001 quality management system certification, environmental management certification, occupational health and safety management certification, and other qualification certifications.
Adhering to the business philosophy of “Integrity, Focus, Professionalism, and Efficiency,” the company aspires to become “a manufacturer of advanced equipment and a provider of technical solutions in the biopharmaceutical R&D and production field.”
Official WeChat
